Recombinant Human Acid Phosphatase 2 protein (ab157834)

Overview

Description

  • Nature
    Recombinant
  • Source
    Wheat germ
  • Amino Acid Sequence
    • Species
      Human
    • Sequence
      MAGKRSGWSRAALLQLLLGVNLVVMPPTQARSLRFVTLLYRHGDRSPVKT YPKDPYQEEEWPQGFGQLTKEGMLQHWELGQALRQRYHGFLNTSYHRQEV YVRSTDFDRTLMSAEANLAGLFPPNGMQRFNPNISWQPIPVHTVPITEDR LLKFPLGPCPRYEQLQNETRQTPEYQNESSRNAQFLDMVANETGLTDLTL ETVWNVYDTLFCEQTHGLRLPPWASPQTMQRLSRLKDFSFRFLFGIYQQA EKARLQGGVLLAQIRKNLTLMATTSQLPKLLVYSAHDTTLVALQMALDVY NGEQAPYASCHIFELYQEDSGNFSVEMYFRNESDKAPWPLSLPGCPHRCP LQDFLRLTEPVVPKDWQQECQLASGPADTEVIVALAVCGSILFLLIVLLL TVLFRMQAQPPGYRHVADGEDHA
    • Amino acids
      1 to 423
    • Tags
      proprietary tag N-Terminus

Specifications

Our Abpromise guarantee covers the use of ab157834 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Applications

    Western blot

    ELISA

  • Form
    Liquid
  • Additional notes
    Protein concentration is above or equal to 0.05 mg/ml.
  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped on dry ice. Upon delivery aliquot and store at -80ºC. Avoid freeze / thaw cycles.

    pH: 8.00
    Constituents: 0.31% Glutathione, 0.79% Tris HCl

General Info

  • Alternative names
    • Acid phosphatase 2 lysosomal
    • ACP 2
    • ACP2
    • LAP
    • Lysosomal acid phosphatase
    • Lysosomal acid phosphatase 2
    • PPAL_HUMAN
    see all
  • Involvement in disease
    Defects in ACP2 are a cause of acid phosphatase deficiency (ACPHD) [MIM:200950]. The clinical features are intermittent vomiting, hypotonia, lethargy, opisthotonos, terminal bleeding, and death in early infancy. Lysosomal acid phosphatase is deficient in cultured fibroblasts and multiple tissues.
  • Sequence similarities
    Belongs to the histidine acid phosphatase family.
  • Post-translational
    modifications
    The membrane-bound form is converted to the soluble form by sequential proteolytic processing. First, the C-terminal cytoplasmic tail is removed. Cleavage by a lysosomal protease releases the soluble form in the lysosome lumen.
    N-glycosylated. The intermediates formed during enzymatic deglycosylation suggest that all eight predicted N-glycosylation sites are used.
  • Cellular localization
    Lysosome membrane. Lysosome lumen. The soluble form arises by proteolytic processing of the membrane-bound form.
  • Information by UniProt

Images

  • ab157834 on a 12.5% SDS-PAGE stained with Coomassie Blue.

References

ab157834 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab157834.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up